×
About 11,110 results

ALLMedicine™ Urticaria Center

Research & Reviews  2,534 results

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

Jan 27th, 2023 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Cutaneous neuropeptides: the missing link between psychological stress and chronic infl...
https://doi.org/10.1007/s00403-023-02542-4
Archives of Dermatological Research; Keller JJ

Jan 27th, 2023 - A "brain-skin" connection has been long been observed between chronic stress and chronic inflammatory skin disease including urticaria, psoriasis, atopic dermatitis, and prurigo nodularis. The relationship appears to be bidirectional. Chronic psyc...

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
https://clinicaltrials.gov/ct2/show/NCT04538794

Jan 26th, 2023 - The purpose of the study is to explore the safety, pharmacodynamics, and pharmacokinetics of ascending doses of CDX-0159 in patients with Chronic Spontaneous Urticaria who remain symptomatic despite treatment with antihistamines. There is a screen...

Real-life Study of How to Intensify Treatment With Xolair (OMALIZUMAB) in Chronic Spontaneous Urticaria
https://clinicaltrials.gov/ct2/show/NCT04583475

Jan 26th, 2023 - This is an observational study whose main objective is to estimate the frequency of patients benefiting from an intensification of AOM treatment at 3 months.

A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
https://clinicaltrials.gov/ct2/show/NCT05048342

Jan 26th, 2023 - This is a Phase 3 multi-center, open-label, single arm study investigating the safety, tolerability and efficacy of remibrutinib in participants with CSU inadequately controlled by second generation H1-antihistamines. Inadequate control of CSU by ...

see more →

Guidelines  7 results

The Diagnostic Workup in Chronic Spontaneous Urticaria-What to Test and Why
https://pubmed.ncbi.nlm.nih.gov/33857657/
The Journal of Allergy and Clinical Immunology; Metz M

Jun 3rd, 2021 - In chronic spontaneous urticaria (CSU), the guidelines recommend very limited diagnostic procedures during the routine workup, although additional investigations might be indicated in some patients with CSU. For physicians treating patients with C...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and ma...
https://doi.org/10.1111/all.13397
Allergy Zuberbier T, Aberer W et. al.

Jan 18th, 2018 - This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. I...

Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/...
https://doi.org/10.1111/all.12370
Allergy Zuberbier T, Aberer W et. al.

Jun 6th, 2014 - This methods report describes the process of guideline development in detail. It is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured con...

Sclerotherapy of varicose veins with polidocanol based on the guidelines of the German ...
https://doi.org/10.1111/j.1524-4725.2010.01495.x
Dermatologic Surgery : Official Publication for American ... Rabe E, Pannier F

Jul 16th, 2010 - Sclerotherapy involves the injection of a sclerosing agent for the elimination of intracutaneous, subcutaneous, and transfascial varicose veins. To update guidelines for sclerotherapy of varicose veins. The guidelines for sclerotherapy of varicose...

see more →

Drugs  1,198 results see all →

Clinicaltrials.gov  248 results

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

Jan 27th, 2023 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
https://clinicaltrials.gov/ct2/show/NCT04538794

Jan 26th, 2023 - The purpose of the study is to explore the safety, pharmacodynamics, and pharmacokinetics of ascending doses of CDX-0159 in patients with Chronic Spontaneous Urticaria who remain symptomatic despite treatment with antihistamines. There is a screen...

Real-life Study of How to Intensify Treatment With Xolair (OMALIZUMAB) in Chronic Spontaneous Urticaria
https://clinicaltrials.gov/ct2/show/NCT04583475

Jan 26th, 2023 - This is an observational study whose main objective is to estimate the frequency of patients benefiting from an intensification of AOM treatment at 3 months.

A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
https://clinicaltrials.gov/ct2/show/NCT05048342

Jan 26th, 2023 - This is a Phase 3 multi-center, open-label, single arm study investigating the safety, tolerability and efficacy of remibrutinib in participants with CSU inadequately controlled by second generation H1-antihistamines. Inadequate control of CSU by ...

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
https://clinicaltrials.gov/ct2/show/NCT05528861

Jan 26th, 2023 - This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002) in adult subjects with H-1 antihistamine refractory chronic spontaneous urticaria. Subjects...

see more →

News  433 results

Cutaneous Manifestations in Hereditary Alpha Tryptasemia
https://www.mdedge.com/dermatology/article/260439/contact-dermatitis/cutaneous-manifestations-hereditary-alpha-tryptasemia
Allison Kranyak, MD, Marshall Shuler, MD et. al.

Jan 3rd, 2023 - Hereditary alpha tryptasemia (HaT), an autosomal-dominant disorder of tryptase overproduction, was first described in 2014 by Lyons et al. 1 It has been associated with multiple dermatologic, allergic, gastrointestinal (GI) tract, neuropsychiatric,.

Incidental skin finding
https://www.mdedge.com/familymedicine/article/260254/dermatology/incidental-skin-finding
MDedge Family Medicine;

Dec 19th, 2022 - This patient was given a diagnosis of cutaneous mastocytosis. The condition was previously known as urticaria pigmentosa, but in 2016 the World Health Organization reclassified the disease to better suit its pathophysiology as a myeloid cell disor.

Fast Five Quiz: Urticaria (Hives)
https://www.medscape.com/viewarticle/984987

Dec 12th, 2022 - According to the American College of Allergy, Asthma & Immunology, urticaria, also known as hives, has a lifetime incidence of about 20%. Many substances and situations — especially work environments — can trigger urticaria, which usually starts a...

Doctors Can Combat Urticaria Misinformation With Empathy and Facts
https://www.medscape.com/viewarticle/984393

Nov 21st, 2022 - Patients suffering from chronic urticaria can easily find bogus causes and treatments online, and providers need to refute the falsehoods with facts, a research letter suggests. "Chronic urticaria can have a major psychological impact, leaving pat...

Chronic Spontaneous Urticaria: Longer Treatment and Up-Dosing Benefit Patients With Poor Omalizumab Response
https://www.medscape.com/viewarticle/984096

Nov 15th, 2022 - LOUISVILLE, Kentucky — Patients with chronic spontaneous urticaria (CSU) who experienced a suboptimal response with 12-week omalizumab treatment showed benefit with longer treatment duration or up-dosing of the monoclonal antibody, a study found. ...

see more →

Patient Education  24 results see all →